The Myasthenia Gravis Disease Market is witnessing a significant surge, driven by advancements in targeted biologic therapies and growing global awareness of rare autoimmune conditions. Myasthenia Gravis (MG), a chronic autoimmune neuromuscular disorder, disrupts communication between nerves and muscles, causing varying degrees of skeletal muscle weakness. With more precise diagnostics and novel therapeutics entering the market, patients now have access to better treatment outcomes and improved quality of life.
Global Myasthenia Gravis Disease Market size and share is currently valued at USD 2.60 billion in 2024 and is anticipated to generate an estimated revenue of USD 6.19 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 9.1% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
Market Overview
Myasthenia Gravis arises when the immune system mistakenly produces antibodies that interfere with neuromuscular junction function, particularly targeting acetylcholine receptor antibodies or other proteins such as MuSK. This interference prevents muscles from contracting properly, leading to fatigue and weakness, especially in the face, eyes, throat, and limbs.
Traditionally managed with corticosteroids, anticholinesterase agents, and immunosuppressants, the market has evolved to include biologics, complement inhibitors, FcRn blockers, and IVIG therapies. Innovations in these areas offer promise for refractory patients and those with generalized MG who respond poorly to first-line treatments.
Market Segmentation
The Myasthenia Gravis market can be segmented based on treatment type, disease type, route of administration, and end-user.
1. By Treatment Type:
Cholinesterase Inhibitors (e.g., Pyridostigmine)
Corticosteroids and Immunosuppressants
Monoclonal Antibody Therapies (e.g., Eculizumab, Ravulizumab, Efgartigimod)
IVIG and Plasmapheresis
Emerging FcRn Antagonists
2. By Disease Type:
Generalized Myasthenia Gravis (gMG)
Ocular Myasthenia Gravis
Neonatal and Congenital MG
3. By Route of Administration:
Oral
Intravenous (IV)
Subcutaneous (SC)
4. By End User:
Hospitals and Clinics
Specialty Neurology Centers
Homecare Settings
Monoclonal antibodies are the fastest-growing segment, expected to dominate the market due to their targeted mechanisms, efficacy, and fewer side effects.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market
Country-wise Market Trends
United States
The U.S. remains the largest market for MG treatment due to strong RD activity, high prevalence rates, and early adoption of biologics. In 2024, the U.S. accounted for over 45% of global sales, with treatments like Soliris, Ultomiris, and Vyvgart gaining widespread reimbursement. The FDA continues to prioritize rare disease therapies through accelerated approval pathways, supporting rapid market entry.
Germany
Germany leads the European MG market due to its robust rare disease registry and structured healthcare system. German neurologists have been early adopters of neuromuscular junction dysfunction diagnostics, driving increased detection rates. The country also plays a critical role in global clinical trials for pipeline drugs such as zilucoplan and batoclimab.
Japan
Japan is witnessing steady market growth, backed by supportive regulatory policies from the Pharmaceuticals and Medical Devices Agency (PMDA). The prevalence of MG has increased among the aging population, and new biologics have been integrated into treatment protocols. Japan’s national insurance system ensures widespread access to innovative therapies, contributing to strong adoption of monoclonal antibody therapies.
China
China represents the fastest-growing market for Myasthenia Gravis treatment. With increasing disease awareness, expanding urban neurology networks, and national rare disease frameworks, diagnosis and treatment rates are climbing. The Chinese Center for Disease Control has launched awareness campaigns, and local biopharmaceuticals are entering the market with affordable biosimilars and IVIG therapies.
United Kingdom
In the UK, the National Health Service (NHS) and NICE (National Institute for Health and Care Excellence) have adopted a cautious approach to approving high-cost biologics. However, Vyvgart and Soliris have been granted limited access through specialized care units. The UK also sees high enrollment in MG clinical trials through the UK Neuromuscular Disease Registry.
India
India’s MG market is still in the early stages but shows promise. Urban centers are improving diagnosis and treatment capacity. Generic IVIG and affordable corticosteroids are the mainstay of therapy, while private hospitals are increasingly experimenting with acetylcholine receptor antibody testing and immunosuppressive therapy. High biologic costs, however, remain a barrier in the public sector.
Brazil
Brazil leads Latin America in MG market development, with federal reimbursement programs supporting therapies for rare diseases. The government’s Unified Health System (SUS) enables equitable access to treatments, including IVIG and plasmapheresis. However, high-cost biologics remain restricted to private sector availability.
South Korea
South Korea has emerged as a regional hub for rare disease research and treatment. With strong domestic pharmaceutical innovation, the country supports research into MG-related biomarkers and neuromuscular diagnostics. National insurance policies facilitate access to IVIG and immunosuppressive drugs, with limited but growing availability of biologics.
Key Companies
The Myasthenia Gravis market is competitive, with global players developing novel solutions alongside regional companies striving to improve access and affordability.
Alexion Pharmaceuticals (AstraZeneca)
Alexion leads the market with its blockbuster drugs Soliris (eculizumab) and Ultomiris (ravulizumab), both approved for generalized MG. The company continues to invest in expanding indications and developing next-generation complement inhibitors.
Argenx SE
Argenx has gained traction with efgartigimod (Vyvgart), the first FcRn antagonist approved for MG. The company is expanding into new geographies and indications while conducting Phase III trials for subcutaneous formulations and additional autoimmune conditions.
UCB Pharma
UCB is in the late stages of developing zilucoplan, a subcutaneous C5 complement inhibitor, with potential approval expected by 2026. Following its acquisition of Ra Pharmaceuticals, UCB is focused on rare autoimmune diseases and MG-specific solutions.
Hoffmann-La Roche Ltd.
Roche is exploring B-cell and T-cell modulation therapies applicable to neuromuscular diseases. While not yet dominant in MG, the company is building a portfolio that may extend to MG in the future.
Grifols S.A.
Grifols is a global leader in IVIG therapy, widely used in MG flare management. It is expanding its plasma collection network to meet rising demand and enhance supply chain stability in the wake of rising autoimmune disease burdens.
Octapharma AG
Octapharma is another IVIG provider known for high-quality plasma-derived treatments. Its global footprint includes partnerships with hospitals and specialty clinics for fast distribution in over 100 countries.
Bio-Thera Solutions
Based in China, Bio-Thera is developing biosimilars to existing MG biologics, offering cost-effective alternatives for markets in Asia and Latin America. The company is expected to disrupt the pricing of monoclonal antibody therapies upon broader approval.
Final Outlook
The Myasthenia Gravis Disease Market is entering a transformative phase where monoclonal antibody therapies, FcRn blockers, and enhanced diagnostics for acetylcholine receptor antibodies are changing the standard of care. While traditional therapies remain foundational, innovation is paving the way for personalized, targeted solutions.
As awareness and diagnosis improve, particularly in Asia and Latin America, the global market will benefit from better patient outcomes and increased treatment equity. However, key challenges such as treatment cost, accessibility in developing regions, and long-term safety management must be addressed collaboratively by governments, pharmaceutical companies, and advocacy groups.
More Trending Reports by Polaris Market Research:
Cancer or Tumor Profiling Market
Refurbished Medical Imaging Equipment Market
Virtual Clinical Trials Market
Diaphragm Pacing Therapy System Market
Scientific Data Management System Market
Anti-Biofim Wound Dressing Market
Vaccine Storage Packaging Market
Automated Liquid Handling Technologies Market
Artificial Tendons and Ligaments Market
Targeted DNA RNA Sequencing Market
Cellular Starting Materials Market
